Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (DE:FDY) has released an update.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co has allocated RMB180 million from its A-share public issuance proceeds to subscribe to a low-risk structured deposit product with Bank of China, set to mature on 1 July 2024. The investment guarantees principal and a minimum return, with an expected annualized return rate between 1.2000% and 2.2111% over a 91-day term, linked to the USD/CHF spot rate.
For further insights into DE:FDY stock, check out TipRanks’ Stock Analysis page.